Abstract: This presentation will focus on the doctor's perspective on outcome prediction. Starting points are questions arising in daily practice of allogeneic stem cell transplantation (alloSCT). The goal of the session is to link published data and statistical know-how to these everyday questions, such as giving a prognosis for a specific patient or determining the best moment for an intervention to prevent relapse. For this purpose the difference between risk factor analyses and true outcome prediction for new patients will be discussed and challenges in the use and interpretation of scores and predictive models will be addressed. Outcome prediction after alloSCT based on risk factors known prior to transplantation will be reviewed. Results from large multivariate regression analyses and validated scoring systems will be compared in terms of utility, challenges and limitations to answer everyday questions. More specifically the following topics will be addressed in this presentation: the assumption of causality, confounding factors, interactions between risk factors and specific model assumptions. Next the need for visualization of results from risk factor analyses and limitations will be addressed. In this context the question will be addressed why it is difficult to interpret hazard ratios. A specific challenge is the visualization of the impact of multiple risk factors on competing risks outcomes. Balanced and biased approaches for visualization will be shown. Finally, the need for cross-validation of scoring systems will be highlighted and examples will be discussed. Disclosure of Interest: None declared. Abstract: The purpose of this presentation is to give a general overview of statistical concepts relevant for prediction models for competing risks outcomes in stem cell transplantation (SCT). The presentation will cover general aspects, like the purpose of prediction models -the distinction between etiological research and prediction will be addressed by the first presentation in the session. Aspects of model building will be considered next, in particular the choice between Cox models based on cause-specific hazards versus Fine & Gray models, and practical choices to be made, such as covariate selection, how to deal with missing data and with time-dependent information (e.g., onset of aGvHD). After having constructed a candidate model, checking model assumptions and model validation become important. Checking the proportional hazards assumption and checking functional form of covariates is not straightforward when the prediction model is based on Fine & Gray regression. Ways of presenting the final results of the model will be examined. A useful graphical representation is obtained, for instance, by grouping patients into equally sized risk groups, based on the linear predictor of the risk model. With respect to model validation, predictive measures like the concordance measure of discrimination and prediction error will be reviewed. Finally, the issue of overfitting and the need for internal and external validation will be discussed. All steps in the construction and internal validation of models will be illustrated using an ongoing project on 1638 MDS patients who received an allogeneic stem cell transplantation from an HLA-identical sibling or a matched unrelated donor between 1995 and 2012 and who were reported to the EBMT registry. The aim of the project is to construct a series of prediction models for relapse in the first two years after transplantation, with non-relapse mortality as a competing risk. Disclosure of Interest: None declared.
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